Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Authors' conclusion
In VERTIS CV patients, ertugliflozin reduced the likelihood of insulin initiation, delayed the time to insulin initiation by up to ∼1.8 years, and reduced insulin dose requirements vs placebo, without increasing hypoglycemia events.
Study context
- Population
- Patients with T2D and atherosclerotic CVD in VERTIS CV; mean T2D duration 13.0 years, HbA1c 8.2%
- Comparison
- Ertugliflozin 5 mg or 15 mg vs placebo once daily
- Primary endpoint
- Insulin requirements: time to insulin initiation (insulin-naïve) and change in insulin dose (baseline insulin)
- Follow-up
- Mean 3.5 years
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Insulin initiation in insulin-naïve patients (n=4348, 53%)
Each group vs placeboHazard ratio (95% CI)
Ertugliflozin 5 mg
0.70(0.58–0.84)
Ertugliflozin 15 mg
0.64(0.53–0.78)
Days
- Estimated delay in reaching 10% cumulative incidence of insulin initiation vs placebo, ertugliflozin 5 mg
- 399
- Estimated delay in reaching 10% cumulative incidence of insulin initiation vs placebo, ertugliflozin 15 mg
- 669
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| ≥20% increase in insulin dose in patients on baseline insulin (n=3898, 47%)Ertugliflozin 5 mgvs Placebo | 0.62 (0.52–0.75) | |
| ≥20% increase in insulin dose in patients on baseline insulin (n=3898, 47%)Ertugliflozin 15 mgvs Placebo | 0.51 (0.41–0.62) | |
| 0.512Hazard ratio (log scale) |
Safety
- Incidence of hypoglycaemia events not increased with ertugliflozin
Original publication
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. J Clin Endocrinol Metab. Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →